RecruitingNon-muscle Invasive Bladder Cancer (NMIBC)
Using Urine Tumor DNA to De-Intensify Surveillance in Non-Muscle Invasive Bladder Cancer
Eligible age
18+ yrs
Accepts
All genders
Locations
1 state
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The goal of this clinical trial is to use urine tumor DNA (utDNA) as an indicator for non-muscle invasive bladder cancer to identify patients suitable for less frequent cystoscopy surveillance.
Sponsor: Lahey Clinic
You may qualify if…
- ✓ AUA high-risk bladder cancer1
- ✓ Received induction BCG or gemcitabine/docetaxel
- ✓ Negative initial post-induction therapy assessment (negative cytology and cystoscopy +/- biopsy)
You may not qualify if…
- ✕ High-risk NMIBC within 3 years
- ✕ Prior induction intravesical therapy
- ✕ Variant histology
- ✕ Concurrent upper tract disease
Where it's recruiting
Massachusetts
Burlington
Source: ClinicalTrials.gov · NCT07187063 · last updated 2026-11-03